Last reviewed · How we verify
Sugammadex injection
Sugammadex is a selective relaxant binding agent that encapsulates and inactivates steroidal neuromuscular blocking agents, rapidly reversing neuromuscular blockade.
Sugammadex is a selective relaxant binding agent that encapsulates and inactivates steroidal neuromuscular blocking agents, rapidly reversing neuromuscular blockade. Used for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery, Reversal of deep neuromuscular blockade in anesthetized patients.
At a glance
| Generic name | Sugammadex injection |
|---|---|
| Also known as | Sugammadex, Group A, Sugammadex 100Mg/ml Intravenous Solution |
| Sponsor | University of California, Irvine |
| Drug class | Selective relaxant binding agent |
| Target | Steroidal neuromuscular blocking agents (rocuronium, vecuronium, pancuronium) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Sugammadex works by forming a tight 1:1 complex with steroidal neuromuscular blocking drugs (rocuronium, vecuronium, pancuronium) through host-guest chemistry, effectively removing them from the neuromuscular junction and plasma. This allows acetylcholine to restore normal neuromuscular transmission without requiring acetylcholinesterase inhibitors. The drug enables rapid and complete reversal of neuromuscular blockade induced during anesthesia.
Approved indications
- Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery
- Reversal of deep neuromuscular blockade in anesthetized patients
Common side effects
- Transient increase in heart rate
- Hypotension
- Nausea
- Vomiting
- Recurrence of neuromuscular blockade
Key clinical trials
- The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery (PHASE4)
- Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection (PHASE4)
- Sugammadex v.s. Neostigmine/Glycopyrrolate (NA)
- Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery (PHASE4)
- Minimal Flow Anesthesia and Infection Risk (NA)
- The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group (PHASE4)
- The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach (PHASE4)
- Perioperative Respiratory Adverse events_sugammadex (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |